Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization

1 May 2025

Abstract excerpt

BACKGROUND: Admission to hospital with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is associated with a high risk of morbidity and mortality. Biologic treatment reduces COPD exacerbations in patients with eosinophilic inflammation. Mepolizumab, a monoclonal antibody to interleukin 5, reduces eosinophilic inflammation, but its effects on future hospitalization and mortality are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Chronic Obstructive Pulmonary Disease (COPD) Research
Share to Delphi Technique in Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40305842
DOI: 10.1056/evidoa2500012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mepolizumab for COPD with Eosinophilic Phenotype following HospitalizationPMID 40305842Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.Semantic proximity Read ↗

Burden of disease associated with a COPD eosinophilic phenotype.Semantic proximity Read ↗

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic PhenotypeSemantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Eosinophilic phenotype was associated with better clinical remission in elderly but not middle-aged patients with acute exacerbations of COPDSemantic proximity Read ↗

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

The effect of biologics on lung function improvements among severe eosinophilic asthma patients with partial reversibility or fixed obstructive defects: A retrospective analysisSemantic proximity Read ↗

COPD exacerbation phenotypes in a real-world five year hospitalisation cohort.Semantic proximity Read ↗

Eosinophilic phenotype was associated with better early clinical remission in elderly patients but not middle-aged patients with acute exacerbations of COPD.Semantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.